Ursodeoxycholic Acid Drug Product Consumption Market Synopsis:
In this report, LP Information covers the present scenario with the base year being 2017 and the growth prospects of global Ursodeoxycholic Acid Drug Product market for 20182023.
Ursodeoxycholic Acid is an important clinical drug in the treatment of gallstones, cholecystitis, PBC, and PSC and has broad market prospects. In previous work, ursodeoxycholic acid was prepared by traditional organic synthesis.
The classification of Ursodeoxycholic Acid Drug Product includes Capsule and Tablet. And the proportion of Capsule in 2017 is about 94.8%, and the proportion is in decreasing trend from 2013 to 2018, In China, the major product is tablet, and with low concentration UDCA, and the price is also low than other manufacturers. The major products of Dr. Falk Pharma, Daewoong Pharmaceutical, Teva are capsule.
Ursodeoxycholic Acid Drug Product can be applied in Gallstone, Hepatopathy, Biliary Disease and Other. The most of Ursodeoxycholic Acid Drug Product is used in Gallstone, and the market share of that is about 36.5% in 2017.
North America is the largest sales place, with a sales market share nearly 30% in 2017. Following North America, Europe is the second largest sales place with the Sales market share of 22.1%. Ursodeoxycholic Acid Drug Product market in Asia Pacific region is expected to exhibit the highest growth rate especially in the developing Asian countries like China & India.
Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, etc. are the global leading manufactures in the world. In the future, more generic manufacturers will enter into this industry.
In North America, Epic Pharma is leading manufacturers, Teva, Lannett and Mylan are major suppliers of Ursodeoxycholic Acid Drug Product in USA market. In China, Dr. Falk Pharma is leading manufacturers, the market share is about 81% in 2017. In Japan, Mitsubishi Tanabe Pharma is leading manufacturers, the market share is about 52% in 2017. In Korea, Daewoong Pharmaceutical is leading manufacturers, the market share is about 86.1% in 2017
Over the next five years, LPILP Information projects that Ursodeoxycholic Acid Drug Product will register a 11.9% CAGR in terms of revenue, reach US$ 1900 million by 2023, from US$ 970 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Ursodeoxycholic Acid Drug Product market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Segmentation by application:
This report also splits the market by region:
Middle East & Africa
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Dr. Falk Pharma
Mitsubishi Tanabe Pharma
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
To study and analyze the global Ursodeoxycholic Acid Drug Product consumption value & volume by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Ursodeoxycholic Acid Drug Product market by identifying its various subsegments.
Focuses on the key global Ursodeoxycholic Acid Drug Product manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Ursodeoxycholic Acid Drug Product with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industryspecific challenges and risks.
To project the consumption of Ursodeoxycholic Acid Drug Product submarkets, with respect to key regions along with their respective key countries.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.